Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule?
- PMID: 17262987
Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule?
Abstract
Tau protein, the major constituent of neurofibrillary tangles in Alzheimer's disease (AD) and related tauopathies, is classified as intrinsically disordered protein (IDP). IDPs in contrast to globular proteins contain high proportion of polar and charged amino acids in their sequence, which results in the absence of a well-defined three-dimensional structure of the free protein. Structural flexibility of IDPs is required to perform their important role in many cellular processes. In the course of tauopathies, highly soluble disordered tau protein acquires rigid fold and forms highly insoluble filaments. Beneficial intrinsic disorder transforms into a fatal order: is it a coincidence, or is there an underlying reason for preferential IDPs assembly? In this review we present the structural characteristics of tau protein filamentous lesions in AD and discuss the tendency of IDPs to assembly and to form amyloid deposits (Ref: 65).
Similar articles
-
Alzheimer's-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay.Anal Biochem. 2006 Dec 15;359(2):230-7. doi: 10.1016/j.ab.2006.09.031. Epub 2006 Oct 19. Anal Biochem. 2006. PMID: 17081491
-
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Exp Neurol. 2010 Jun;223(2):304-10. doi: 10.1016/j.expneurol.2009.08.031. Epub 2009 Sep 8. Exp Neurol. 2010. PMID: 19744482 Free PMC article. Review.
-
Mechanisms of tau self-aggregation and neurotoxicity.Curr Alzheimer Res. 2011 Sep;8(6):608-14. doi: 10.2174/156720511796717258. Curr Alzheimer Res. 2011. PMID: 21605046 Review.
-
X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease.FEBS Lett. 2007 Dec 22;581(30):5872-8. doi: 10.1016/j.febslet.2007.11.067. Epub 2007 Dec 3. FEBS Lett. 2007. PMID: 18061582
-
Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.Prog Neurobiol. 2011 Jan;93(1):99-110. doi: 10.1016/j.pneurobio.2010.10.006. Epub 2010 Nov 5. Prog Neurobiol. 2011. PMID: 21056617 Review.
Cited by
-
The dark side of Alzheimer's disease: unstructured biology of proteins from the amyloid cascade signaling pathway.Cell Mol Life Sci. 2020 Oct;77(20):4163-4208. doi: 10.1007/s00018-019-03414-9. Epub 2020 Jan 2. Cell Mol Life Sci. 2020. PMID: 31894361 Free PMC article.
-
Chemoinformatics Analyses of Tau Ligands Reveal Key Molecular Requirements for the Identification of Potential Drug Candidates against Tauopathies.Molecules. 2021 Aug 20;26(16):5039. doi: 10.3390/molecules26165039. Molecules. 2021. PMID: 34443629 Free PMC article.
-
Tau-mediated synaptic damage in Alzheimer's disease.Transl Neurosci. 2015 Oct 23;6(1):214-226. doi: 10.1515/tnsci-2015-0023. eCollection 2015. Transl Neurosci. 2015. PMID: 28123806 Free PMC article. Review.
-
Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments.Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Oct 1;68(Pt 10):1181-5. doi: 10.1107/S1744309112030382. Epub 2012 Sep 25. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012. PMID: 23027743 Free PMC article.
-
Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy.Cell Mol Neurobiol. 2009 Sep;29(6-7):793-8. doi: 10.1007/s10571-009-9355-9. Epub 2009 Feb 13. Cell Mol Neurobiol. 2009. PMID: 19214739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical